ArticleThe Journal of allergy and clinical immunology2009
Phenotypic predictors of long-term response to inhaled corticosteroid and leukotriene modifier therapies in pediatric asthma.
Article in The Journal of allergy and clinical immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it, 115 citations in OpenAlex.
- Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.American journal of respiratory and critical care medicine · 2011Guideline
- Biomarkers to Predict Response to Inhaled Corticosteroids and Long-Acting Muscarinic Antagonists in Adolescents and Adults with Mild Persistent Asthma.Annals of the American Thoracic Society · 2022Trial
- Phenotypes of Recurrent Wheezing in Preschool Children: Identification by Latent Class Analysis and Utility in Prediction of Future Exacerbation.The journal of allergy and clinical immunology. In practice · 2019Trial
- Individualized therapy for persistent asthma in young children.The Journal of allergy and clinical immunology · 2016Trial
- Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma.The Journal of allergy and clinical immunology · 2014Trial
- Predictors of response to tiotropium versus salmeterol in asthmatic adults.The Journal of allergy and clinical immunology · 2013Trial
- Cost-effectiveness analysis of fluticasone versus montelukast in children with mild-to-moderate persistent asthma in the Pediatric Asthma Controller Trial.The Journal of allergy and clinical immunology · 2011Trial
- Urinary leukotriene E4/exhaled nitric oxide ratio and montelukast response in childhood asthma.The Journal of allergy and clinical immunology · 2010Trial
- Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids.The New England journal of medicine · 2010Trial
- Markers of Differential Response to Inhaled Corticosteroid Treatment Among Children with Mild Persistent Asthma.The journal of allergy and clinical immunology. In practiceTrial
- Assessment of Fraction of Exhaled Nitric Oxide and Soluble Receptor for Advanced Glycation End Products Biomarkers for Jordanian Asthmatic Children.Journal of asthma and allergy · 2023Article
- Allergic Asthma in the Era of Personalized Medicine.Journal of personalized medicine · 2022Review
- Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes.The journal of allergy and clinical immunology. In practice · 2020Article
- Challenges and choices in the pharmacological treatment of non-severe pediatric asthma: A commentary for the practicing physician.The World Allergy Organization journal · 2019Article
- Asthma and Corticosteroid Responses in Childhood and Adult Asthma.Clinics in chest medicine · 2019Review
- Clinical Utility Of The Exhaled Nitric Oxide (NO) Measurement With Portable Devices In The Management Of Allergic Airway Inflammation And Asthma.Journal of asthma and allergy · 2019Article
- Measurement of Exhaled Nitric Oxide in Children: A Comparison Between NObreath® and NIOX VERO® Analyzers.Allergy, asthma & immunology research · 2018Article
- A simple prediction tool for inhaled corticosteroid response in asthmatic children.BMC pulmonary medicine · 2017Article
- Exhaled nitric oxide: Not associated with asthma, symptoms, or spirometry in children with sickle cell anemia.The Journal of allergy and clinical immunology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
Abstract
backgroundIn children with mild-to-moderate persistent asthma, identification of phenotypic predictors to guide selection of a controller regimen is essential.
objectiveWe sought to identify phenotypic characteristics having predictive value for the difference in treatment responses between twice-daily fluticasone and once-daily montelukast.
methodsData from the Pediatric Asthma Controller Trial were assessed with multivariate analysis. Outcomes included the change in asthma control days (ACDs), FEV(1), peak expiratory flow, and time to first asthma exacerbation measured over a 1-year treatment period.
resultsThe mean age was 9.6 +/- 2.1 years, 60% were male, 50% had a parental history of asthma, and 78% had positive aeroallergen skin prick test responses. The mean percent predicted prebronchodilator FEV(1) was 97.8% +/- 12.9%, the median PC(20) value was 0.93 mg/mL, and the median exhaled nitric oxide (eNO) level was 25.2 ppb. A history of parental asthma best predicted the expected treatment benefit with fluticasone compared with montelukast in terms of gain in ACDs (adjusted P = .02) and time to first exacerbation (adjusted P = .05). Increased baseline eNO levels predicted the differential treatment response for fluticasone regarding the gain in ACDs (adjusted P = .01). Prior inhaled corticosteroid (ICS) use (adjusted P = .01) and low PC(20) values (adjusted P = .03) each predicted the expected treatment benefit with fluticasone over montelukast regarding time to first exacerbation. No phenotypic characteristics predicted treatment benefits for montelukast over fluticasone for either outcome.
conclusionsPhysicians treating children with a parental history of asthma, increased eNO levels, low PC(20) values, or a history of ICS use can expect the best long-term outcomes with ICS therapy compared with treatment with leukotriene receptor antagonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.